Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3625-3632

  Inaba, Hiroto ^a   Coustan Smith, Elaine ^b   Cao, Xueyuan ^a   Pounds, Stanley B ^a   Shurtleff, Sheila A ^a   Wang, Kathleen Y ^a   Raimondi, Susana C ^a   Onciu, Mihaela ^a   Jacobsen, Jeffrey ^a   Ribeiro, Raul C ^a   Dahl, Gary V ^c   Bowman, W Paul ^d   Taub, Jeffrey W ^e   Degar, Barbara ^f   Leung, Wing ^a   Downing, James R ^a   Pui, Ching Hon ^a   Rubnitz, Jeffrey E ^a   Campana, Dario ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d Risk Evaluation to Achieve Cardiovascular Health   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBF BETA PROTEIN; ETO PROTEIN; MYH11 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL STRUCTURE; EVENT FREE SURVIVAL; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MYELOBLAST; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MONTE CARLO METHOD; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84867603927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5323     Document Type: Article

References (48)

1. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010:7-12, 2010
2. Brüggemann M, Schrauder A, Raff T, et al: Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24:521-535, 2010
3. Buccisano F, Maurillo L, Spagnoli A, et al: Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 21:582-588, 2009
4. Kern W, Bacher U, Haferlach C, et al: The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 23:379-390, 2010
5. Shook D, Coustan-Smith E, Ribeiro RC, et al: Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 9:S281-S285, 2009 (suppl 3)
6. Grimwade D, Vyas P, Freeman S: Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 22:656-663, 2010
7. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 101:3398-3406, 2003 (Pubitemid 36857920)
8. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al: Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 123:243-252, 2003 (Pubitemid 37305058)
9. Langebrake C, Creutzig U, Dworzak M, et al: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 24:3686-3692, 2006 (Pubitemid 46630545)
10. van der Velden VH, Sluijs-Geling A, Gibson BE, et al: Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 24:1599-1606, 2010
11. San Miguel JF, Vidriales MB, López-Berges C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746-1751, 2001
12. Kern W, Voskova D, Schoch C, et al: Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078-3085, 2004 (Pubitemid 39517010)
13. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 26:4944-4951, 2008
14. Marcucci G, Livak KJ, Bi W, et al: Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12:1482-1489, 1998 (Pubitemid 28442398)
15. Tobal K, Newton J, Macheta M, et al: Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95:815-819, 2000 (Pubitemid 30062701)
16. Guerrasio A, Pilatrino C, De Micheli D, et al: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16:1176-1181, 2002 (Pubitemid 34618856)
17. Viehmann S, Teigler-Schlegel A, Bruch J, et al: Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 17:1130-1136, 2003 (Pubitemid 36722244)
18. Marcucci G, Caligiuri MA, Döhner H, et al: Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 15:1072-1080, 2001 (Pubitemid 32717277)
19. Buonamici S, Ottaviani E, Testoni N, et al: Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 99:443-449, 2002
20. van der Reijden BA, Simons A, Luiten E, et al: Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. Br J Haematol 118:411-418, 2002 (Pubitemid 34994641)
21. Leroy H, de Botton S, Grardel-Duflos N, et al: Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 19:367-372, 2005 (Pubitemid 40403312)
22. Perea G, Lasa A, Aventín A, et al: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 20:87-94, 2006
23. Corbacioglu A, Scholl C, Schlenk RF, et al: Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 28:3724-3729, 2010
24. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukemia: Results of the AML02 multicenter trial. Lancet Oncol 11:543-552, 2010
25. Raimondi SC, Chang MN, Ravindranath Y, et al: Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 94:3707-3716, 1999
26. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Creutzig U, Zimmermann M, Lehrnbecher T, et al: Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 24:4499-4506, 2006 (Pubitemid 46646248)
29. Tsukimoto I, Tawa A, Horibe K, et al: Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 27:4007-4013, 2009
30. Cooper TM, Franklin J, Gerbing RB, et al: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 118:761-769, 2012
31. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
32. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
33. Löwenberg B, Pabst T, Vellenga E, et al: Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027-1036, 2011
34. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999 (Pubitemid 29500811)
35. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
36. Chen Y, Cortes J, Estrov Z, et al: Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: Prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29:2507-2513, 2011
37. Lane S, Saal R, Mollee P, et al: A ≥ 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma 49:517-523, 2008 (Pubitemid 351298336)
38. Scholl C, Schlenk RF, Eiwen K, et al: The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90:1626-1634, 2005 (Pubitemid 41814986)
39. Bergmann L, Miething C, Maurer U, et al: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217-1225, 1997 (Pubitemid 27314159)
40. Cilloni D, Gottardi E, Fava M, et al: Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 102:773-774, 2003 (Pubitemid 36842006)
41. Weisser M, Kern W, Rauhut S, et al: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416-1423, 2005 (Pubitemid 41148947)
42. Lapillonne H, Renneville A, Auvrignon A, et al: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515, 2006 (Pubitemid 46638771)
43. Cilloni D, Renneville A, Hermitte F, et al: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 27:5195-5201, 2009
44. Meshinchi S, Stirewalt DL, Alonzo TA, et al: Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 111:4930-4933, 2008
45. Kottaridis PD, Gale RE, Langabeer SE, et al: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100:2393-2398, 2002
46. Shih LY, Huang CF, Wu JH, et al: Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 100:2387-2392, 2002
47. Krönke J, Schlenk RF, Jensen KO, et al: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709-2716, 2011
48. Brown P, McIntyre E, Rau R, et al: The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 110:979-985, 2007 (Pubitemid 47267437)